Products
Crefmirlimab Biosimilar Dimeric scFv Antibody Fragment (CD8α) for Research
Cat No.: GMP-Bios-INN-1144
Anti-CD8A therapeutic antibody (Pre-made Crefmirlimab biosimilar,scFv Engineered Dimer) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Crefmirlimab (development code IAB 22 M2C) is a scFv dimer antibody targeting CD8. It is developed by ImaginAb for solid tumours, cervical cancer, gastric cancer. It is in Phase III clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1144-1mg | 1mg | 3090 |
| GMP-Bios-INN-1144-10mg | 10mg | |
| GMP-Bios-INN-1144-100mg | 100mg | |
| GMP-Bios-INN-1144-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Crefmirlimab biosimilar, scFv Engineered Dimer, Anti-CD8A Antibody: Anti-CD8/CD8A/CD8a/T-cell surface glycoprotein CD8 alpha chain therapeutic antibody |
| INN Name | Crefmirlimab |
| Target | CD8A |
| Format | scFv Engineered Dimer |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2022 |
| Year Recommended | 2022 |
| Companies | ImaginAb |
| Conditions Approved | na |
| Conditions Active | Solid tumours;Cervical cancer;Gastic cancer |
| Conditions Discontinued | Graft-versus-host disease |
| Production | na |
| Development Tech | na |
